Cardiovascular disease in patients with chronic kidney disease a clinical review

Minerva Urologica e Nefrologica

Volumn 59, Issue 3, 2007, Pages 281-297

  Kaisar, M ^a   Isbel, N ^a   Johnson, D W ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Anemia; Cardiovascular diseases; Kidney failure, chronic; Randomized controlled trials; Statins; Treatment, outcome

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ASCORBIC ACID; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CINACALCET; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE; FLUINDOSTATIN; FOLIC ACID; FOSINOPRIL; GEMFIBROZIL; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANTHANUM CARBONATE; PHOSPHATE BINDING AGENT; PLACEBO; PRAVASTATIN; PYRIDOXINE; RAMIPRIL; RECOMBINANT ERYTHROPOIETIN; ROSUVASTATIN; SEVELAMER; TELMISARTAN; VITAMIN D;

ANEMIA; BONE MINERAL; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; DYSLIPIDEMIA; FOLLOW UP; GLYCEMIC CONTROL; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE REVASCULARIZATION; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERPHOSPHATEMIA; HYPERTRIGLYCERIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INTERMETHOD COMPARISON; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; METABOLIC DISORDER; MINERAL METABOLISM; MORTALITY; OBESITY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANEMIA; BONE DISEASES, METABOLIC; CARDIOMYOPATHIES; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; HUMANS; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIAS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; OXIDATIVE STRESS; RENAL DIALYSIS; RISK FACTORS;

EID: 36749031174     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. United States Renal Data Systems. Annual Data Report. Minneapolis, MN: USRDS; 2006.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.
3. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(Suppl 3):112-9.
4. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004;15:1307-15.
5. Foley RN, Herzog CA, Collins AJ. Smoking and cardiovascular outcomes in dialysis patients: the United States Renal Data System Wave 2 study. Kidney Int 2003;63:1462-7.
6. Anavekar NS, Chertow GM, Fan D, Solomon SD, Kober L, Rouleau JL et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1296-305.
7. Keough-Ryan TM, Kiberd BA, Dipchand CS, Cox JL, Rose CL, Thompson KJ et al. Outcomes of acute coronary syndrome in a large Canadian cohort: impact of chronic renal insufficiency, cardiac interventions, and anemia. Am J Kidney Dis 2005;46:845-55.
8. Kennedy R, Case C, Fathi R, Johnson D, Isbel N, Marwick TH. Does renal failure cause an atherosclerotic milieu in patients with end- stage renal disease? Am J Med 2001;110: 198-204.
9. Coca SG, Krumholz HM, Garg AX, Parikh CR. Under representation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 2006;296:1377-84.
10. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004;110:1557-63.
11. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G et al. German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-48.
12. Stegmayr B, Brannstrom M, Bucht B, Crougneau V, Dimeny E, Ekspong A et al. Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled end-point study. Scand J Urol Nephrol 2005;39:489-97.
13. Holdaas H, Fellstrom BC, Jardine AG, Holme I, Nyberg G, Fauchald P et al. Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361:2024-31.
14. Holdaas H, Fellstrom BC, Cole E, Nyberg G, Olsson AG, Pedersen TR et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 2005;5:2929-36.
15. Landray M, Baigent C, Leaper C, Adu D, Altmann P, Armitage J et al. The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis 2006;47: 385-95.
16. Fellstrom BC, Zannad F, Schmieder R, Holdaas H, Jardine AG. Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study. Curr Control Trials Cardiovasc Med 2005;6:9.
17. Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int 2004;66:1123-30.
18. Zannad F, Kessler M, Lehert P,Grunfeld JP, Thuilliez C, Leizorovicz A et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized controlled trial of fosinopril and implications for future studies. Kidney Int 2006;70:1318-24.
19. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003;41:1438-44.
20. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62.
21. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994;330:877-84.
22. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996;49:1379-85.
23. Walker R, Irish A, McDonald SP, Craig J, McMahon L. CARI Guideline: Cardiovascular risk factors in chronic kidney disease. www.cari.org.au. 2006. Sydney, Australia, Australian and New Zealand Society of Nephrology.
24. Nobakht Haghighi A, Broumand B, D'Amico M, Locatelli F, Ritz E. The epidemiology of end-stage renal disease in Iran in an international perspective. Nephrol Dial Transplant 2002;17:28-32.
25. Thomas M, Tsalamandris C, MacIsaac R, Jerums G. Anaemia in diabetes: an emerging complication of microvascular disease. Curr Diabetes Rev 2005;1:107-26.
26. Brommand B. Diabetes: changing the fate of diabetics in the dialysis unit. Blood Purif 2007;25:39-47.
27. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int 1995;47:1703-20.
28. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
29. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000;342:381-9.
30. Morika T, Emoto M, Tabata T, Shoji T, Tahara H, Kishimoto H et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 2001;24:909-13.
31. Fleischmann E, Teal N, Dudley J, May W, Bower JD, Salahudeen AK. Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. Kidney Int 1999;55:1560-7.
32. Beddhu S, Pappas LM, Ramkumar N, Samore M: Effects of body size and body composition on survival in hemodialysis patients. J Am Soc Nephrol 2003;14:2366-72.
33. Kalantar-Zadeh K, Kopple JD, Kilpatrick RD, McAllister CJ, Shinaberger CS, Gjertson DW et al. Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. Am J Kidney Dis 2005;46:489-500.
34. de Mutsert RD, Snijder MB, Beer FS, Seidell JC, Boeschoten EW, Krediet DT et al. Association between body mass index and mortality is similar in the hemodialysis population and the general population at high age and equal duration of follow-up. Netherlands Cooperative Study on the Adequacy of Dialysis-2 (NECOSAD) study group. J Am Soc Nephrol 2007;18:967-74.
35. Combe C, Chauveau P, Laville M, Fouque D, Azar R; French Study Group Nutrition in Dialysis. Influence of nutritional factors and hemodialysis adequacy on the survival of 1,610 French patients. Am J Kidney Dis 2001;37(Suppl 2):81-8.
36. Kasiske BL, Cangro CB, Hariharan S, Hricik DE, Kerman RH, Roth D et al. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant 2001;(Suppl 2):3-95.
37. Johnson DW, Isbel NM, Brown AM, Kay TD, Franzen K, Hawley CM et al. The effect of obesity on renal transplant outcomes. Transplantation 2002;74:675-81.
38. Marks WH, Florence LS, Chapman PH, Precht AF, Perkinson DT. Morbid obesity is not a contraindication to kidney transplantation. Am J Surg 2004;187: 635-8.
39. Kahn JK, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV, Hartzler GO. Short- and long-term outcome of percutaneous transluminal coronary angioplasty in chronic dialysis patients. Am Heart J 1990;119:484-9.
40. Le Feuvre C, Dambrin G, Helft G, Beygui F, Touam M, Grünfeld JP et al. Clinical outcome following coronary angioplasty in dialysis patients: a case-control study in the era of coronary stenting. Heart 2001;85:556-60.
41. Hemmelgarn BR, Southern D, Culleton BF, Mitchell LB, Knudtson ML, Ghali WA; Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease (APPROACH) Investigators. Survival after coronary revascularization among patients with kidney disease. Circulation 2004;110:1890-5.
42. Zakeri R, Freemantle N, Barnett V, Lipkin GW, Bonser RS, Graham TR et al. Relation between mild renal dysfunction and outcomes after coronary artery bypass grafting. Circulation 2005;112(Suppl 9):270-5.
43. Edwards NC, Steeds RP, Ferro CJ, Townend JN. The treatment of coronary artery disease in patients with chronic kidney disease. QJM 2006;99:723-36.
44. Herzog CA, Ma JZ, Collins AJ. Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation 2002;106:2207-11.
45. Reddan DN, Szczech LA, Tuttle RH, Shaw LK, Jones RH, Schwab SJ et al. Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. J Am Soc Nephrol 2003;14:2373-80.
46. Manske CL, Wang Y, Rector T, Wilson RF, White CW. Coronary revascularisation in insulin-dependent diabetic patients with chronic renal failure. Lancet 1992;340:998-1002.
47. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002;162:1401-8.
48. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996;49:1379-85.
49. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999;10:610-9.
50. Madore F, Lowrie EG, Brugnara C, Lew NL, Lazarus JM, Bridges K et al. Anemia in hemodialysis patients: variables affecting this outcome predictor. J Am Soc Nephrol 1997;8:1921-9.
51. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90.
52. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M et al.; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98.
53. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D et al.; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-84.
54. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007;369:381-8.
55. Tobu M, Iqbal O, Fareed D, Chatha M, Hoppensteadt D, Bansal V et al. Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. Clin Appl Thromb Hemost 2004;10:225-32.
56. Taylor JE, McLaren M, Henderson IS, Belch JJ, Stewart WK. Prothrombotic effect of erythropoietin in dialysis patients. Nephrol Dial Transplant 1992;7:235-9.
57. Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 1999;33:821-8.
58. IV NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 2001;37(Suppl 1):182-238.
59. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003;63:793-08.
60. Suliman ME, Qureshi AR, Barany P, Stenvinkel P, Filho JC, Anderstam B et al. Hyperhomocysteinemia, nutritional status and cardiovascular disease in hemodialysis patients. Kidney Int 2000;57:1727-35.
61. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004;15:420-6.
62. Righetti M, Ferrario GM, Milani S, Serbelloni P, La Rosa L, Uccellini M et al. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. Med Sci Monit 2003;9:119-24.
63. Vianna AC, Mocelin AJ, Matsuo T, Morais-Filho D, Largura A, Delfino VA et al. Uremic hyperhomocysteinemia: a randomized controlled trial of folate treatment for the prevention of cardiovascular events. Hemodial Int 2007;11:210-6.
64. Zoungas S, McGrath BP, Branley P, Kerr PG, Muske C, Wolfe R et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol 2006;47:1108-16.
65. Righetti M, Serbelloni P, Milani S, Ferrario GM. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif 2006;24:379-86.
66. Jamison RL, Hartigan P, Gaziano JM, Fortmann SP, Goldfarb DS, Haroldson JA et al. Design and statistical issues in the homocysteinemia in kidney and end-stage renal disease (HOST) study. Clin Trials 2004;1:451-60.
67. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18.
68. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimtmetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005;68:1793-800.
69. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52.
70. Block G, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68:1815-24.
71. Asmus HG, Braun J, Krause R, Brunkhorst R, Holzer H, Schulz W et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 2005;20:1653-61.
72. Block G, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71:438-41.
73. Suki W, Zabaneh R, Cangiano J. The DCOR trial - a prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients. J Am Soc Nephrol 2005;16:P0745.
74. Tepel M, Echelmeyer M, Orie NN, Zidek W. Increased intracellular reactive oxygen species in patients with end-stage renal failure: effect of hemodialysis. Kidney Int 2000;58:867-72.
75. Becker BN, Himmelfarb J, Henrich WL, Hakim RM. Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 1997;8:475-86.
76. Boaz M, Matas Z, Biro A, Katzir Z, Green M, Fainaru M et al. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int 1999;56:1078-83.
77. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003;107:992-5.
78. Boaz M, Smetana S, Weinstein, Matas Z, Gafter U, Iaina A et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000;356:1213-8.
79. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation study investigators. N Engl J Med 2000;342:154-60.
80. Nanayakkara PW, van Guldener C, ter Wee PM, Scheffer PG, van Ittersum FJ, Twisk JW et al. Effect of a treatment strategy consisting of pravastatin, vitamin E and homocysteine lowering on carotid intima-media thickness, endothelial function and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-oxidant Therapy in Chronic renal insufficiency (ATIC) study. Arch Intern Med 2007;167:1262-70.
81. Owen WF, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993;329:1001-6.
82. Collins AJ, Ma JZ, Umen A, Keshaviah P. Urea index and other predictors of hemodialysis patient survival. Am J Kidney Dis 1994;23:272-82.
83. Hakim RM, Breyer J, Ismail N, Schulman G. Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis 1994;23:661-9.
84. Lowrie EG, Laird NM, Parker TF, Sargent JA. Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study. N Engl J Med 1981;305:1176-81.
85. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002;347:2010-9.
86. Delmez JA, Yan G, Bailey J, Beck GJ, Beddhu S, Cheung AK et al. Cerebrovascular disease in maintenance hemodialysis patients: results of the HEMO Study. Am J Kidney Dis 2006;47:131-8.
87. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002;13:1307-20.
88. Lo WK, Ho YW, Li CS, Wong KS, Chan TM, Yu AW et al. Effect of Kt/V on survival and clinical outcome in CAPD patients in a randomized prospective study. Kidney Int 2003;64:649-56.
89. Curtis BM, Levin A, Parfrey PS. Multiple risk factor intervention in chronic kidney disease: management of cardiac disease in chronic kidney disease patients. Med Clin North Am 2005;89:511-23.
90. Curtis BM, Ravani P, Malberti F, Kennett F, Taylor PA, Djurdjev O et al. The short- and long-term impact of multi-disciplinary clinics in addition to standard nephrology care on patient outcomes. Nephrol Dial Transplant 2005;20:147-54.
91. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999;353:617-22.
92. Isbel NM, Haluska B, Johnson DW, Beller E, Hawley CM, Marwick TH. Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function. Am Heart J 2006;151:745-53.
93. Harris LE, Luft FC, Rudy DW, Kesterson JG, Tierney WM. Effects of multidisciplinary case management in patients with chronic renal insufficiency. Am J Med 1998;105:464-71.